- Home
- VYNE vs ACHL Comparison
VYNE vs ACHL Comparison
Compare VYNE & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- ACHL
- Stock Information
- Founded
- VYNE 2003
- ACHL 2016
- Country
- VYNE United States
- ACHL United Kingdom
- Employees
- VYNE N/A
- ACHL N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VYNE Health Care
- ACHL Health Care
- Exchange
- VYNE Nasdaq
- ACHL Nasdaq
- Market Cap
- VYNE 41.9M
- ACHL 40.4M
- IPO Year
- VYNE 2018
- ACHL 2021
- Fundamental
- Price
- VYNE $2.90
- ACHL $1.05
- Analyst Decision
- VYNE Strong Buy
- ACHL Hold
- Analyst Count
- VYNE 2
- ACHL 3
- Target Price
- VYNE $6.88
- ACHL $2.83
- AVG Volume (30 Days)
- VYNE 122.3K
- ACHL 141.2K
- Earning Date
- VYNE 11-07-2024
- ACHL 11-14-2024
- Dividend Yield
- VYNE N/A
- ACHL N/A
- EPS Growth
- VYNE N/A
- ACHL N/A
- EPS
- VYNE N/A
- ACHL N/A
- Revenue
- VYNE $493,000.00
- ACHL N/A
- Revenue This Year
- VYNE $32.31
- ACHL N/A
- Revenue Next Year
- VYNE N/A
- ACHL N/A
- P/E Ratio
- VYNE N/A
- ACHL N/A
- Revenue Growth
- VYNE 39.27
- ACHL N/A
- 52 Week Low
- VYNE $1.57
- ACHL $0.63
- 52 Week High
- VYNE $4.09
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- VYNE 59.02
- ACHL 54.94
- Support Level
- VYNE $2.65
- ACHL $1.01
- Resistance Level
- VYNE $3.05
- ACHL $1.08
- Average True Range (ATR)
- VYNE 0.23
- ACHL 0.04
- MACD
- VYNE -0.05
- ACHL -0.00
- Stochastic Oscillator
- VYNE 34.57
- ACHL 39.31
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.